COVID-19 related risk of in-hospital death in Silesia, Poland

Kowalska, Małgorzata; Barański, Kamil; Brożek, Grzegorz; Kaleta-Pilarska, Angelina; Zejda, Jan

doi:10.20452/pamw.15893

Cited by 13 publications

(18 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This reduction was not the result of a lack of hospital beds but rather caused by the limited degree of clinical signs and symptoms, which allowed for home management of these patients. The overall mortality in our whole study cohort (8.0%) was similar to that previously reported in the SOT population [15] and also in the local general population [16], although in a recent meta-analysis of a large SOT cohort, the overall mortality was as high as 18.6%. Of note, among ICU patients we noted extremely high mortality, similar to the recent report in comparable transplant [17] and dialysis cohorts [18].…”

Section: Discussionsupporting

confidence: 89%

Clinical insights into the role of immunosuppression and its disturbances in solid organ transplant recipients with coronavirus disease 2019

Kolonko¹,

Kuczaj²,

Musialik³

et al. 2021

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 89%

Clinical insights into the role of immunosuppression and its disturbances in solid organ transplant recipients with coronavirus disease 2019

Kolonko¹,

Kuczaj²,

Musialik³

et al. 2021

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

“…This observation is in line with epidemiological data on COVID-19 mortality in different age groups [ 21 , 22 , 24 ]. A study in a group of 2830 patients hospitalized with COVID-19 in one of the administrative regions in Poland (Silesia Voivodeship) showed that COVID-19 deaths were associated with male sex (OR: 1.52; 95%CI: 1.17–1.96), older age (OR: 6.11; 95%CI: 4.5–8.31), and the presence of 2 (OR: 3.05; 95%CI: 2.07–4.51) or ≥3 coexisting diseases (OR: 4.78; 95%CI: 3.52–6.49) [ 25 ]. In our study when controlled by age and sex, the presence of at least one comorbidity more than doubled the COVID 19–related risk of in-hospital death.…”

Section: Discussionmentioning

confidence: 99%

“…In our study when controlled by age and sex, the presence of at least one comorbidity more than doubled the COVID 19–related risk of in-hospital death. The differences may result from the fact that the study from Silesia Voivodeship [ 25 ] was limited to the first wave of COVID-19 pandemic (March–June 2020) and our study includes data covering the entire 2020 (two waves of COVID-19 pandemic).…”

Section: Discussionmentioning

confidence: 99%

Characteristics and Clinical Outcomes of 116,539 Patients Hospitalized with COVID-19—Poland, March–December 2020

Gujski

Jankowski

Rabczenko

et al. 2021

Viruses

View full text Add to dashboard Cite

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes Coronavirus Disease 2019 (COVID-19). This study aimed to characterize patients hospitalized with COVID-19 in Poland between March and December 2020, as well as to identify factors associated with COVID 19–related risk of in-hospital death. This retrospective analysis was based on data from the hospital discharge reports on COVID-19 patients hospitalized in Poland between March and December 2020. A total of 116,539 discharge reports on patients hospitalized with COVID-19 were analyzed. Among patients with COVID-19, 21,490 (18.4%) died during hospitalization. Patients over 60 years of age (OR = 7.74; 95%CI: 7.37–8.12; p < 0.001), men (OR = 1.42; 95%CI: 1.38–1.47; p < 0.001) as well as those with cardiovascular diseases (OR = 1.51; 95%CI: 1.46–1.56; p < 0.001) or disease of the genitourinary system (OR = 1.39; 95%CI: 1.31–1.47; p < 0.001) had much higher odds of COVID 19–related risk of in-hospital death. The presence of at least one comorbidity more than doubled the COVID 19–related risk of in-hospital death (OR = 2.23; 95%CI: 2.14–2.32; p < 0.01). The following predictors of admission to ICU were found in multivariable analysis: age over 60 years (OR: 2.03; 95%CI: 1.90–2.16), male sex (OR: 1.79; 95%CI: 1.69–1.89), presence of at least one cardiovascular disease (OR: 1.26; 95%CI: 1.19–1.34), presence of at least one endocrine, nutritional and metabolic disease (OR: 1.17; 95%CI: 1.07–1.28).

show abstract

“…In Poland, by the end of 2020, the COVID-19-related overall mortality rate was 2.1% with an 11.5% estimated in-hospital fatality rate for COVID-19 during the first wave of the pandemic [ 9 ]. The treatment of COVID-19 with tocilizumab was initiated in April 2020, as the drug was already registered in Poland.…”

Section: Introductionmentioning

confidence: 99%

Changes in Inflammatory Markers after Administration of Tocilizumab in COVID-19: A Single-Center Retrospective Study

Olewicz‐Gawlik

Ginter-Matuszewska

Kamińśki

et al. 2021

JCM

View full text Add to dashboard Cite

The COVID-19 pandemic requires the development of effective methods for the treatment of severe cases. We aimed to describe clinical outcomes and changes in inflammatory markers in Polish patients treated with tocilizumab. The medical charts of SARS-CoV-2-positive patients treated in the Department of Infectious Diseases between 4 March and 2 September 2020 were retrospectively analyzed. The patients who received tocilizumab according to the Polish Association of Epidemiologists and Infectiologists guidelines were selected for the study. We identified 29 individuals who received tocilizumab, out of whom 11 (37.9%) died. The individuals who died had significantly higher maximal interleukin-6 (IL-6) and lactate dehydrogenase (LDH) serum levels than survivors. After administration of tocilizumab, further increase in LDH and IL-6 was a prognostic factor for unfavorable outcomes. Among inflammatory markers, 7-day mean of IL-6 serum concentration was the best predictor of death (cut-off: ≥ 417 pg/mL; area under ROC curve = 0.81 [95% Confidence Interval: 0.63–0.98]). The serum concentrations of inflammatory markers before administration of tocilizumab did not predict the outcome, whereas IL-6 and LDH measurements after administration of tocilizumab seemed to be of predictive value.

show abstract

COVID-19 related risk of in-hospital death in Silesia, Poland

Cited by 13 publications

References 13 publications

Clinical insights into the role of immunosuppression and its disturbances in solid organ transplant recipients with coronavirus disease 2019

Clinical insights into the role of immunosuppression and its disturbances in solid organ transplant recipients with coronavirus disease 2019

Characteristics and Clinical Outcomes of 116,539 Patients Hospitalized with COVID-19—Poland, March–December 2020

Changes in Inflammatory Markers after Administration of Tocilizumab in COVID-19: A Single-Center Retrospective Study

Contact Info

Product

Resources

About